13 / 30
Analysis of
Overall Survival
Median OS, d (mo)
Sorafenib
Not reached
Placebo
1110 (36.5)
Median OS was not reached in the sorafenib arm and was 36.5 months in the placebo arm.
1,2
HR = 0.88 (95% CI: 0.63-1.24)
P
= 0.24, 1-sided
Survival Probability, %
0
100
200
300
400
500
600
700
800
900
1300
0
10
20
40
60
80
100
30
50
70
90
Time From Randomization, d
1200
1100
1000
1. Brose MS, et al. Presented at ASCO 2014. Abstract 6060. 2. Nexavar Summary of Product Characteristics. Berlin, Germany: Bayer Pharma AG; January 2015.
•
At progression
– 157
(74.8%)
patients receiving placebo had started open-label sorafenib
at the time of this analysis